EDEMA2:EVALUATION OF DX-88'S EFFECTS IN MITIGATING ANGIOEDEMA, AN OPEN LABEL STD

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: This is an open label study designed to assess the safety and effectiveness of repeated dosing of DX-88 in patients with hereditary angeoedema (HAE). Primary endpoints are: >The proportion of successful outcomes i.e., attack resolution begun by four hours after a single dose and maintained for greater than 24 hours after a single dose. > The proportion of patients who have a partial response, that is an initial response to the infusion followed by a relapse 4 - 24 hours after the infustion. > Sa